← FDA DRUG APPROVALS

FDA BLA · BLA761192

NEXOBRID

anacaulase-bcdb

Sponsor: MEDIWOUND, LTD

APPLICATION
BLA761192
TYPE
BLA
ORIGINAL APPROVAL
2022-12-28
LATEST ACTION
2024-08-15
ROUTE
TOPICAL
DOSAGE FORM
GEL
MARKETING STATUS
Prescription

Products

NEXOBRIDPrescription
ANACAULASE-BCDB 8.8% · GEL · TOPICAL

Approval history

2024-08-15Efficacy · Supplement 10 · standardLabelAP
2022-12-28Type 1 - New Molecular Entity · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →